Lexicon Pharmaceuticals (LXRX) Capital Expenditures Growth (1y) (2011 - 2024)
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Capital Expenditures Growth (1y) (2011 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 269.88% |
| Jun 30, 2024 | 79.86% |
| Sep 30, 2023 | 1,975.00% |
| Mar 31, 2023 | 226.32% |
| Dec 31, 2022 | 5,317.39% |
| Sep 30, 2022 | -98.12% |
| Mar 31, 2022 | 100.00% |
| Dec 31, 2021 | -57.41% |
| Sep 30, 2021 | 545.45% |
| Mar 31, 2019 | 75.00% |
| Dec 31, 2018 | 825.00% |
| Sep 30, 2018 | -95.08% |
| Jun 30, 2018 | -78.87% |
| Mar 31, 2018 | -56.52% |
| Dec 31, 2017 | -97.30% |
| Sep 30, 2017 | 281.25% |
| Jun 30, 2017 | 446.15% |
| Mar 31, 2017 | 70.37% |
| Dec 31, 2016 | -39.84% |
| Sep 30, 2016 | -91.30% |